Clinical trials: Adverse Drug Event
Adverse Drug Reaction
Serious Adverse Drug Reaction and Their Preventability
Introduction: Elderly aged over 65 years accounted for around 17.5% of the French general population. Adverse drug reactions (ADR) are common in this population. In elderly subject, prevalence of ADRs ranged from 4.3% to 63.0%.
- Trial name
- SADR (NCT02888834)
- Testing
- Adverse drug reaction
- Where
- France
- Volunteers
- 100 people
- Sponsor
- CHU de Reims
Obsessive-Compulsive Disorder, Anxiety Disorders
Pharmacogenetics of Antidepressant-Induced Disinhibition
The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders…
- Conditions
- Obsessive-Compulsive Disorder, Anxiety Disorders, Major Depressive Disorder, Antidepressant Drug Adverse Reaction
- Trial name
- PGx-AID (NCT03953014)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University of Calgary
Adverse Drug Events
Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy
We tested two interventions to improve the accuracy of medication histories obtained at hospital admission. The interventions target elderly and chronically ill patients prone to erroneous medication histories and resultant…
- Trial name
- NCT02026453
- Testing
- Pharmacist obtains admission medication history, Pharmacy technician obtains admission medication history
- Volunteers
- 306 people
- Sponsor
- Cedars-Sinai Medical Center
Adverse Drug Event, Colon Cancer
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
The purpose of this study is to examine the benefits of a clinical implementation of a DPYD-genotype test to patients starting treatment with fluoropyrimidines (Fluorouracil (5-FU), capecitabine, tegafur).
- Conditions
- Adverse Drug Event, Colon Cancer, Breast Cancer, Pancreas Cancer
- Trial name
- NCT05266300
- Testing
- DPYD genotype
- Where
- Denmark
- Volunteers
- 722 people
- Sponsor
- University of Southern Denmark
Grade 2 Hand-foot Syndrom
Efficacy of the Cosmetic Product "Onco-Repair" on Grade 2 Hand Foot Syndrome
The aim of the study is to assess the restorative efficacy of the cosmetic product "Onco-Repair" vs placebo of the most affected palmer face in subject with grade 2 HFS induced by targeted therapies or conventional chemotherapy.
- Trial name
- OCRP (NCT03612011)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Quanta Medical
Iatrogenic Disease
Incidence of Iatrogenic Diseases on Hospital's Emergency Consultations
French population grows older year after year: 24.3% people were over 60 years old in 2006 against 20.6% in 2000 and the expected number might be over 33% in 2050.
- Trial name
- EIU (NCT03960398)
- Testing
- Iatrogenic disease impact on emergency consultations
- Where
- 2 sites in France
- Volunteers
- 2,500 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Pain
Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain
The purpose of this study is to collect adverse events and identify risk factors in patients that are taking Dolocordralan Extra 25® and Dolocordralan Extra Forte®
- Trial name
- NCT02651363
- Where
- Peru
- Volunteers
- 374 people
- Sponsor
- Bristol-Myers Squibb
Embolism and Thrombosis, Hemorrhage
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
The purpose of this study is to investigate the preventability of serious adverse drug reactions (ADRs) related to the use of direct oral anticoagulants (DOACs).
- Trial name
- ADR-OAC (NCT02720328)
- Testing
- Blood samples for DOAC measurement
- Where
- 2 sites in Belgium
- Volunteers
- 102 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Adverse Drug Event
Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service.
An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant…
- Trial name
- MedeA (NCT06607445)
- Where
- Spain
- Volunteers
- 6,445 people, healthy volunteers welcome
- Sponsor
- Complejo Hospitalario Universitario de Badajoz
Urologic Diseases, Antibacterial Drug Adverse Reaction
Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists
Antimicrobial resistance is one of today''s most urgent public health problems. An important strategy to slow the spread of antimicrobial resistance is the promotion of judicious antimicrobial use.
- Trial name
- NCT04196777
- Testing
- Audit-and-feedback
- Where
- 3 sites in United States
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Iowa City Veterans Affairs Medical Center
Malignancy, Immune Related Adverse Events
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Immunotherapies have improved cancer outcomes, but have a unique profile of immune-related adverse events (irAEs). Biorepositories have been established to collect data and samples to help improve our understanding of irAEs…
- Trial name
- NCT06789601
- Testing
- Informatics system for eligibility monitoring, Standard eligibility monitoring
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Brigham and Women's Hospital
Adverse Drug Reactions
A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women
This was a retrospective cohort study of pregnant women who had received the AdimFlu-S (A/H1N1) influenza vaccine during gestation period. Eligibility into the study was confirmed by chart review.
- Trial name
- NCT01354730
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Hepatitis B, Antiviral Drug Adverse Reaction
Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resistance
To evaluate the efficacy of switching to tenofovir alafenamide (TAF) 25 mg QD versus continued tenofovir disoproxil fumarate (TDF) 300 mg QD in CHB patients with antiviral resistance, as determined by the proportion of…
- Trial name
- NCT03566030
- Testing
- Tenofovir disoproxil fumarate 300mg, Tenofovir Alafenamide 25 mg
- Volunteers
- 300 people
- Sponsor
- Yonsei University
Transitions of Care, General Medicine
PREventing Adverse Events Post-Discharge Through Proactive Identification, Multidisciplinary Communication, and Technology
The goal of this study is to expand the use of previously developed patient safety dashboards and patient-centered discharge checklists to three general medicine units in an affiliated community hospital.
- Conditions
- Transitions of Care, General Medicine, Discharge Checklist, Adverse Event
- Trial name
- PREDICT (NCT05232656)
- Testing
- Pre-Discharge Checklist and Patient Safety Dashboard
- Where
- United States
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Drug Abuse, Harm Reduction
Harm Reduction Intervention for Anabolic-androgenic Steroids Users: a Randomized Controlled Trial
This clinical trial aims to investigate the short and long-term efficacy of a harm reduction intervention in reducing the use of non-clinical anabolic-androgenic steroids (AAS) in abusive users of AAS.
- Conditions
- Drug Abuse, Harm Reduction, Minimization, Harm, Anabolic Steroids Adverse Events
- Trial name
- SOS-RCT-HR (NCT07039539)
- Testing
- harm reduction intervention in non-clinical anabolic-androgenic steroids users
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Medication Errors and Other Product Use Errors and Issues
Meds@HOME App to Support Medication Safety
This study determines whether the mHealth intervention, Meds@HOME, helps caregivers improve medication administration to Children with Medical Complexity (CMC) who use high-risk medications.
- Trial name
- NCT05816590
- Testing
- Med@HOME Mobile App
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- University of Wisconsin, Madison
Stevens-Johnson Syndrome, Lyell Syndrome
Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
Intro: Dermatology department of Henri Mondor Hospital (Creteil, France), is a reference center for toxic bullous diseases and severe cutaneous drug reactions (Stevens-Johnson syndrome (SJS), Lyell syndrome (toxic epidermal…
- Conditions
- Stevens-Johnson Syndrome, Lyell Syndrome, Drug Reactions, AGEP
- Trial name
- NCT03659227
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adverse Drug Reactions
Adverse Drug Event Prevention Using Structured Pharmacist Review
The next four decades will see a marked expansion of the elderly population in Ireland, in particular people aged over 80 yrs. Persons aged over 80 are the highest consumers of prescription medicines in Ireland and have the…
- Trial name
- NCT01467128
- Testing
- Structured expert pharmacist review, No Intervention
- Where
- Ireland
- Volunteers
- 720 people
- Sponsor
- University College Cork
COVID, Drug Effect
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in a health insurance…
- Conditions
- COVID, Drug Effect, Drug Interaction, Adverse Drug Event
- Trial name
- NCT04378881
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Tabula Rasa HealthCare
Inflammatory Disease, Drug Side Effect
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic…
- Conditions
- Inflammatory Disease, Drug Side Effect, Drug Use, Adverse Drug Event
- Trial name
- LOOK-UP (NCT06498167)
- Testing
- Upadacitinib
- Where
- 3 sites in Portugal
- Volunteers
- 150 people
- Sponsor
- Universidade do Porto